stockrow
Friday 6 November 2026
Export ORKA’s income statement to Excel — free account
Oruka Therapeutics, Inc.
ORKA Healthcare Biotechnology
- EPS
- −19.6%
- Free cash flow
- −43.0%
Quarter to June 2026, against a year earlier
102.68
6.66
+6.94%
Follow ORKA
Alert me
Oruka Therapeutics, Inc. (ORKA) Total debt
Oruka Therapeutics, Inc.'s total debt at the end of fiscal 2022 was $383.0K, down 20.7% from $483.0K in fiscal 2021. At the end of the quarter to 30 September 2023 it was $301.0K. Oruka Therapeutics, Inc. ranks 451st of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2022 | $383.0K | (20.70%) |
| FY2021 | $483.0K | 7.33% |
| FY2020 | $450.0K | 1,700.00% |
| FY2019 | $25.0K | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2023 | $301.0K | (8.51%) |
| Jun 2023 | $329.0K | (7.84%) |
| Mar 2023 | $357.0K | (6.79%) |
| Dec 2022 | $383.0K | (6.36%) |
| 11 more quarters | Free account |
Total debt against peers
| Company | Total debt |
|---|---|
| IONS Ionis Pharmaceuticals, Inc. compare | $1.4B |
| MIRM Mirum Pharmaceuticals, Inc. compare | $731.3M |
| LGND Ligand Pharmaceuticals Incorporated compare | $679.9M |
| KOD Kodiak Sciences Inc. compare | $174.5M |
| AXSM Axsome Therapeutics, Inc. compare | $127.3M |
| CGON CG Oncology, Inc. compare | $3.0M |
| IMVT Immunovant, Inc. compare | $614.0K |
| ORKA Oruka Therapeutics, Inc. | $301.0K |
| BLTE Belite Bio, Inc. Sponsored ADR compare | — |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt